Recent Quotes

My Watchlist

Indicators

Acrivon Therapeutics, Inc. - Common Stock (NQ: ACRV )

6.710 +0.020 (+0.30%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	224,296
Open	6.620
Bid (Size)	7.040 (1)
Ask (Size)	7.570 (1)
Prev. Close	6.690
Today's Range	6.510 - 7.180
52wk Range	3.190 - 11.90
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

November 13, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium

October 17, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Performance

YTD	+33.93%	+33.93%
1 Month	+4.19%	+4.19%
3 Month	-7.19%	-7.19%
6 Month	+7.19%	+7.19%
1 Year	+34.47%	+34.47%

More News

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

October 11, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

September 14, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference

September 10, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Host Virtual Investor Event to Review Positive Phase 2 Clinical Data of ACR-368 Presented at ESMO and Pipeline Progress, Including Clinical Candidate ACR-2316

September 09, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q2 2024

August 13, 2024

Via InvestorPlace

Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

August 13, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

ACRV Stock Earnings: Acrivon Therapeutics Beats EPS for Q1 2024

May 14, 2024

Via InvestorPlace

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 14, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

April 25, 2024

Via InvestorPlace

12 Health Care Stocks Moving In Wednesday's After-Market Session

April 24, 2024

Via Benzinga

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

April 24, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

April 16, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable

April 10, 2024

From Acrivon Therapeutics, Inc

Via GlobeNewswire

Crude Oil Down Over 1%; Cognyte Software Shares Plummet

April 09, 2024

Via Benzinga

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

April 09, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session

April 09, 2024

Via Benzinga

Dow Dips 150 Points; Laser Photonics Shares Spike Higher

April 09, 2024

Via Benzinga

Why Is Rail Vision (RVSN) Stock Up 17% Today?

April 09, 2024

Via InvestorPlace

ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost

April 09, 2024

Via InvestorPlace

Acrivon Therapeutics Stock Is Soaring Tuesday: What's Going On?

April 09, 2024

Via Benzinga

Dow Gains Over 50 Points; Neogen Posts Downbeat Earnings

April 09, 2024

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.